Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6995MR)

This product GTTS-WQ6995MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6995MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11649MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ1984MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ11099MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ10120MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ8682MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ7061MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ7485MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ7580MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW